DOV KADMON to Adult
This is a "connection" page, showing publications DOV KADMON has written about Adult.
Connection Strength
0.098
-
Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated Akt. Clin Cancer Res. 2008 Nov 15; 14(22):7511-8.
Score: 0.017
-
Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort. Clin Cancer Res. 2006 Aug 15; 12(16):4872-5.
Score: 0.015
-
Long-term benefits of elective radiotherapy after prostatectomy for patients with positive surgical margins. J Urol. 2006 Jun; 175(6):2097-101; discussion 2101-2.
Score: 0.014
-
The effect of statins on serum prostate specific antigen levels in a cohort of airline pilots: a preliminary report. J Urol. 2005 Jun; 173(6):1923-5.
Score: 0.013
-
Effect of 13-cis-retinoic acid on serum prostate-specific antigen levels in patients with recurrent prostate cancer after radical prostatectomy. Clin Cancer Res. 2000 Oct; 6(10):3845-9.
Score: 0.010
-
Pitfalls in interpreting prostate specific antigen velocity. J Urol. 1996 May; 155(5):1655-7.
Score: 0.007
-
Stromogenic prostatic carcinoma pattern (carcinomas with reactive stromal grade 3) in needle biopsies predicts biochemical recurrence-free survival in patients after radical prostatectomy. Hum Pathol. 2007 Nov; 38(11):1611-20.
Score: 0.004
-
Reliability of remembered International Index of Erectile Function domain scores in men with localized prostate cancer. Urology. 2005 Jan; 65(1):131-5.
Score: 0.003
-
Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate cancer patients. Int J Radiat Oncol Biol Phys. 2004 Jun 01; 59(2):562-71.
Score: 0.003
-
Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer. Urology. 2004 May; 63(5):905-10; discussion 910-1.
Score: 0.003
-
Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data. Int J Radiat Oncol Biol Phys. 2004 Apr 01; 58(5):1520-9.
Score: 0.003
-
Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer--a preliminary report. Int J Radiat Oncol Biol Phys. 2001 Nov 01; 51(3):605-13.
Score: 0.003
-
Unilocular retroperitoneal cyst of mesothelial origin presenting as a renal mass. Arch Pathol Lab Med. 2000 May; 124(5):766-9.
Score: 0.002